IMV Inc
TSX:IMV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
IMV Inc
Operating Income
IMV Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IMV Inc
TSX:IMV
|
Operating Income
-$38.9m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Operating Income
-CA$13.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-96%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Operating Income
$106.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Operating Income
-$373.1m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-45%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Operating Income
-CA$36.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-73%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Operating Income
-$123.2m
|
CAGR 3-Years
-85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
IMV Inc
Glance View
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 97 full-time employees. The company went IPO on 2007-10-24. The firm is using its DPX delivery technology to achieve targeted immune activation. The Company’s lead candidate, maveropepimut-S, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its other candidates include DPX-RSV and DPX-COVID-19. Its DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
See Also
What is IMV Inc's Operating Income?
Operating Income
-38.9m
USD
Based on the financial report for Dec 31, 2021, IMV Inc's Operating Income amounts to -38.9m USD.
What is IMV Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-48%
Over the last year, the Operating Income growth was -26%. The average annual Operating Income growth rates for IMV Inc have been -35% over the past three years , -48% over the past five years .
